StockUS listing USANTXNASDAQHealthcareCapital Destroyer

AN2 Therapeutics Inc(ANTX) Stock Analysis | Healthcare

USD --+0.00%
Reward33Low
Risk35Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 198.07M
Reward Ratingⓘ33 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ35 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ANTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is AN2 Therapeutics Inc?

, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.

AI Brief Pro

The brief on AN2 Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is AN2 Therapeutics Inc?

, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 198.07M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (33)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap198.07M
Beta-0.937
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
820,325 shares
$117k
12,098 shares
$12k
3-6months
441,612 shares
$239k
0
6-9months
1327 shares
$347
0
9-12months
642,784 shares
$43k
0